Myriad's Downside Case Might Not Matter
April 01, 2015 at 15:25 PM EDT
In a report published Wednesday, Barclays analysts maintained an Overweight rating on Myriad Genetics Inc (NASDAQ: MYGN), with a price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.